Cenovus Energy Inc. (TSX: CVE) (NYSE: CVE) announced today the
early tender results for its tender offers to purchase for cash
certain of its outstanding series of Notes.
Cenovus also announced it has increased the
previously announced Pool 2 Maximum Amount (as defined below) from
$250,000,000 to $500,000,000. The Pool 1 Maximum Amount (as defined
below) and the Series Tender Cap (as defined below) remain
unchanged at $500,000,000 and $250,000,000, respectively.
References to "$" in this news release are to
United States dollars, unless otherwise indicated.
Details of tender offersCenovus
initially offered to purchase for cash: (i) up to $500,000,000
aggregate purchase price, excluding accrued and unpaid interest
(the “Pool 1 Maximum Amount”), of its 5.250% Notes due 2037, 4.450%
Notes due 2042, 5.200% Notes due 2043, 4.400% Notes due 2029,
5.400% Notes due 2047 and 4.250% Notes due 2027 (collectively, the
“Pool 1 Notes”) and (ii) up to $250,000,000 aggregate purchase
price, excluding accrued and unpaid interest (the “Pool 2 Maximum
Amount” and, together with the Pool 1 Maximum Amount, the “Maximum
Amounts”), of its 6.800% Notes due 2037 and 6.750% Notes due 2039
(collectively, the “Pool 2 Notes” and, together with the Pool 1
Notes, the “Notes”), subject to prioritized acceptance levels
listed in the table below (“Acceptance Priority Levels”) and the
terms and conditions of the tender offers.
Cenovus has amended such tender offers to increase
the previously announced Pool 2 Maximum Amount from $250,000,000 to
$500,000,000. All other terms of the tender offers as previously
announced in the offer to purchase dated September 5, 2023 (as
amended and supplemented hereby, the “Offer to Purchase”) remain
unchanged. Cenovus refers investors to the Offer to Purchase for
the complete terms and conditions of the tender offers.
As of the previously announced early tender date
and time of 5:00 p.m., New York City time, on September 18, 2023
(the “Early Tender Date”), according to information provided by
D.F. King & Co., Inc., the tender and information agent for the
tender offers, the aggregate principal amount of each series of
Notes listed in the table below had been validly tendered and not
validly withdrawn in each tender offer. Withdrawal rights for the
Notes expired at 5:00 p.m., New York City time, on the Early Tender
Date.
|
Title of Security |
CUSIP/ISIN |
Principal AmountOutstanding |
Maximum Amount |
Acceptance
PriorityLevel(1) |
Series Tender Cap |
Principal Amount Tendered at Early Tender
Date |
Pool 1 Tender Offers |
5.250% Notes due 2037 |
15135UAP4 / US15135UAP4915135UAN9 / US15135UAN90 (144A)C23555AG7 /
USC23555AG79 (Reg S) |
$583,102,000 |
$500,000,000(2) |
1 |
$250,000,000(3) |
$400,387,000 |
4.450% Notes due 2042 |
15135UAH2 / US15135UAH23 |
$97,004,000 |
2 |
N/A |
$5,688,000 |
5.200% Notes due 2043 |
15135UAK5 / US15135UAK51 |
$28,549,000 |
3 |
N/A |
$1,614,000 |
4.400% Notes due 2029 |
448055AP8 / US448055AP89 |
$239,598,000 |
4 |
N/A |
$57,128,000 |
5.400% Notes due 2047 |
15135UAR0 / US15135UAR0515135UAQ2 / US15135UAQ22 (144A)C23555AH5 /
USC23555AH52 (Reg S) |
$799,872,000 |
5 |
N/A |
$571,507,000 |
Pool 2 Tender Offers |
6.800% Notes due 2037 |
448055AD5 / US448055AD59 |
$386,773,000 |
$500,000,000(4) |
1 |
N/A |
$195,551,000 |
6.750% Notes due 2039 |
15135UAF6 / US15135UAF66 |
$935,422,000 |
2 |
N/A |
$398,009,000 |
(1) |
|
Subject to the Maximum Amounts, the Series Tender Cap and
proration, the principal amount of each series of Notes that is
expected to be purchased in each tender offer will be determined in
accordance with the applicable Acceptance Priority Level (in
numerical priority order) specified in this column. |
(2) |
|
Represents the maximum aggregate purchase price payable, excluding
accrued and unpaid interest, in respect of the 5.250% Notes due
2037, 4.450% Notes due 2042, 5.200% Notes due 2043, 4.400% Notes
due 2029 and 5.400% Notes due 2047 which may be purchased in the
tender offers. |
(3) |
|
The Pool 1 Notes with Acceptance Priority Level 1 (the “Capped
Notes”) are subject to an aggregate principal amount sublimit of
$250,000,000 (the “Series Tender Cap”). |
(4) |
|
Represents the maximum aggregate purchase price payable, excluding
accrued and unpaid interest, in respect of the 6.800% Notes due
2037 and 6.750% Notes due 2039 which may be purchased in the tender
offers. |
|
|
|
The terms and conditions of the tender offers are
described in the Offer to Purchase. Cenovus expects to elect to
exercise its right to make payment on September 20, 2023 (the
“Early Settlement Date”) for Notes validly tendered prior to or at
the Early Tender Date and accepted for purchase. Cenovus intends to
fund the purchase of validly tendered and accepted Notes on the
Early Settlement Date with cash on hand and certain short-term
borrowings.
Because the Pool 1 Notes validly tendered and not
validly withdrawn prior to or at the Early Tender Date have an
aggregate purchase price, excluding accrued and unpaid interest,
that exceeds the Pool 1 Maximum Amount, Cenovus does not expect to
accept for purchase all Pool 1 Notes that have been validly
tendered and not validly withdrawn prior to or at the Early Tender
Date. Rather, subject to the Pool 1 Maximum Amount, the Series
Tender Cap and the Acceptance Priority Levels set forth in the
table above, in each case as further described in the Offer to
Purchase, Cenovus expects to accept for purchase all of the 4.450%
Notes due 2042, 5.200% Notes due 2043 and 4.400% Notes due 2029
validly tendered and not validly withdrawn prior to or at the Early
Tender Date. Because the aggregate principal amount of Capped Notes
validly tendered and not validly withdrawn prior to or at the Early
Tender Date exceeds the Series Tender Cap, Cenovus expects to
accept for purchase $250,000,000 aggregate principal amount of the
Capped Notes validly tendered and not validly withdrawn prior to or
at the Early Tender Date on a prorated basis using a proration
factor to be announced following the determination of the Total
Consideration (as defined herein). Cenovus expects to accept for
purchase the 5.400% Notes due 2047 validly tendered and not validly
withdrawn prior to or at the Early Tender Date on a prorated basis
using a proration factor to be announced following the
determination of the Total Consideration. Cenovus does not expect
to accept for purchase any 4.250% Notes due 2027. As described
further in the Offer to Purchase, Notes tendered and not accepted
for purchase will be promptly credited to the tendering holder’s
account. Additionally, because the Pool 1 Notes validly tendered
and not validly withdrawn prior to or at the Early Tender Date have
an aggregate purchase price, excluding accrued and unpaid interest,
that exceeds the Pool 1 Maximum Amount, Cenovus does not expect to
accept for purchase any Pool 1 Notes tendered after the Early
Tender Date on a subsequent settlement date. The tender offers for
the Pool 1 Notes will expire at 5:00 p.m., New York City time, on
October 3, 2023, or any other date and time to which Cenovus
extends the applicable tender offer, unless earlier terminated.
Because the Pool 2 Notes validly tendered and not
validly withdrawn prior to or at the Early Tender Date have an
aggregate purchase price, excluding accrued and unpaid interest,
that exceeds the Pool 2 Maximum Amount, Cenovus does not expect to
accept for purchase all Pool 2 Notes that have been validly
tendered and not validly withdrawn prior to or at the Early Tender
Date. Rather, subject to the Pool 2 Maximum Amount and the
Acceptance Priority Levels set forth in the table above, in each
case as further described in the Offer to Purchase, Cenovus expects
to accept for purchase all of the 6.800% Notes due 2037 validly
tendered and not validly withdrawn prior to or at the Early Tender
Date. Cenovus expects to accept for purchase the 6.750% Notes due
2039 validly tendered and not validly withdrawn prior to or at the
Early Tender Date on a prorated basis using a proration factor to
be announced following the determination of the Total
Consideration. As described further in the Offer to Purchase, Notes
tendered and not accepted for purchase will be promptly credited to
the tendering holder’s account. Additionally, because the Pool 2
Notes validly tendered and not validly withdrawn prior to or at the
Early Tender Date have an aggregate purchase price, excluding
accrued and unpaid interest, that exceeds the Pool 2 Maximum
Amount, Cenovus does not expect to accept for purchase any Pool 2
Notes tendered after the Early Tender Date on a subsequent
settlement date. The tender offers for the Pool 2 Notes will expire
at 5:00 p.m., New York City time, on October 3, 2023, or any other
date and time to which Cenovus extends the applicable tender offer,
unless earlier terminated.
The applicable consideration (the “Total
Consideration”) offered per $1,000 principal amount of each series
of Notes validly tendered and accepted for purchase pursuant to the
applicable tender offer will be determined in the manner described
in the Offer to Purchase by reference to the applicable fixed
spread for such Notes plus the applicable yield based on the
bid-side price of the applicable U.S. Treasury Reference Security
at 10:00 a.m., New York City time, on September 19, 2023 (the
“Price Determination Date”). Only holders of Notes who validly
tendered and did not validly withdraw their Notes prior to or at
the Early Tender Date are eligible to receive the applicable Total
Consideration, which is inclusive of the applicable early tender
payment, for Notes accepted for purchase. Holders will also receive
accrued and unpaid interest on Notes validly tendered and accepted
for purchase from the applicable last interest payment date up to,
but not including, the Early Settlement Date.
Promptly after the Price Determination Date,
Cenovus will issue a news release specifying, among other things,
(i) the aggregate principal amount of each series of Notes validly
tendered and not validly withdrawn as of the Early Tender Date and
expected to be accepted for purchase in each tender offer, (ii) the
proration factor for the Capped Notes, the 5.400% Notes due 2047
and the 6.750% Notes due 2039 and (iii) the Total Consideration for
each series of Notes expected to be accepted for purchase.
All Notes accepted for purchase will be retired and
cancelled and will no longer remain outstanding obligations of
Cenovus.
Cenovus’s obligation to accept for payment and to
pay for Notes validly tendered and not validly withdrawn in the
tender offers is subject to the satisfaction of certain conditions
described in the Offer to Purchase. Cenovus reserves the right,
subject to applicable law, to (i) waive any and all conditions to
any of the tender offers, (ii) extend or terminate any of the
tender offers, (iii) further increase or decrease either of the
Maximum Amounts and/or increase, decrease or eliminate the Series
Tender Cap, or (iv) otherwise further amend any of the tender
offers. Cenovus may take any action described in clauses (i)
through (iv) above with respect to one or more tender offers
without having to do so for all tender offers.
Information relating to the tender
offersGoldman Sachs & Co. LLC, BMO Capital Markets
Corp. and MUFG Securities Americas Inc. are the dealer managers for
the tender offers. Investors with questions regarding the terms and
conditions of the tender offers may contact Goldman Sachs & Co.
LLC at (800) 828-3182 (toll-free) or by email at
gs-lm-nyc@ny.email.gs.com, BMO Capital Markets Corp. at (833)
418-0762 (toll-free) or (212) 702-1840 (collect) or by email at
LiabilityManagement@bmo.com and MUFG Securities Americas Inc. at
(877) 744-4532 (toll-free) or (212) 405-7481 (collect). D.F. King
& Co., Inc. is the tender and information agent for the tender
offers. Investors with questions regarding the procedures for
tendering Notes may contact the tender and information agent by
email at cve@dfking.com, or by phone at (212) 269-5550 (for banks
and brokers only) or (888) 644-5854 (for all others, toll-free).
Beneficial owners may also contact their broker, dealer, commercial
bank, trust company or other nominee for assistance.
The full details of the tender offers, including
complete instructions on how to tender Notes, are included in the
Offer to Purchase. Holders are strongly encouraged to read
carefully the Offer to Purchase, including materials incorporated
by reference therein, because they contain important information.
The Offer to Purchase may be obtained from D.F. King & Co.,
Inc., free of charge, by calling (212) 269-5550 (for banks and
brokers only) or (888) 644-5854 (for all others, toll-free).
This news release does not constitute an offer to
purchase, or a solicitation of an offer to sell, or the
solicitation of tenders with respect to the Notes. No offer,
solicitation, purchase or sale will be made in any jurisdiction in
which such an offer, solicitation or sale would be unlawful. The
tender offers are being made solely pursuant to the Offer to
Purchase made available to holders of the Notes. None of Cenovus or
its affiliates, their respective boards of directors, the dealer
managers, the tender and information agent or the trustee, with
respect to any series of Notes, is making any recommendation as to
whether or not holders should tender or refrain from tendering all
or any portion of their Notes in response to the tender offers.
Holders are urged to evaluate carefully all information in the
Offer to Purchase, consult their own investment and tax advisors
and make their own decisions whether to tender Notes in the tender
offers, and, if so, the principal amount of Notes to tender.
Advisory
Forward-looking InformationThis
news release contains certain forward‐looking statements and
forward‐looking information (collectively referred to as
“forward‐looking information”) within the meaning of applicable
securities legislation about Cenovus’s current expectations,
estimates and projections about the future of the company, based on
certain assumptions made in light of experiences and perceptions of
historical trends. Although Cenovus believes that the expectations
represented by such forward‐looking information are reasonable,
there can be no assurance that such expectations will prove to be
correct.
Forward-looking information in this document is
identified by words such as “may”, “will”, “expect” or similar
expressions and includes suggestions of future outcomes, including
statements about: the purchase of the Notes and the timing thereof;
the expected sources of funds for the tender offers; the deadlines,
determination dates and settlement dates regarding the tender
offers; increasing or decreasing the Maximum Amounts and/or
increasing, decreasing or eliminating the Series Tender Cap; the
payment of accrued and unpaid interest; the use of a proration
factor in respect of the Capped Notes, the 5.400% Notes due 2047
and the 6.750% Notes due 2039; and the series of Notes to be
accepted for purchase pursuant to the tender offers.
Developing forward-looking information involves
reliance on a number of assumptions and consideration of certain
risks and uncertainties, some of which are specific to Cenovus and
others that apply to the industry generally. The factors or
assumptions on which the forward‐looking information in this news
release are based include, but are not limited to: risks related to
the acceptance of any tendered Notes, the availability of funding
for the tender offers on acceptable terms, the expiration and
settlement of the tender offers, the satisfaction of conditions to
the tender offers, whether the tender offers will be consummated in
accordance with the terms set forth in the Offer to Purchase or at
all, and the timing of any of the foregoing.
The risk factors and uncertainties that could cause
actual results to differ materially from the forward‐looking
information in this news release include, but are not limited to:
risks identified under “Risk Management and Risk Factors” and
“Advisory” in Cenovus’s Management’s Discussion and Analysis
(MD&A) for the year ended December 31, 2022.
Except as required by applicable securities laws,
Cenovus disclaims any intention or obligation to publicly update or
revise any forward‐looking statements, whether as a result of new
information, future events or otherwise. Readers are cautioned that
the foregoing lists are not exhaustive and are made as at the date
hereof. Events or circumstances could cause actual results to
differ materially from those estimated or projected and expressed
in, or implied by, the forward‐looking information. For additional
information regarding Cenovus’s material risk factors, the
assumptions made, and risks and uncertainties which could cause
actual results to differ from the anticipated results, refer to
“Risk Management and Risk Factors” and “Advisory” in Cenovus’s
MD&A for the periods ended December 31, 2022 and June 30,
2023, and to the risk factors, assumptions and uncertainties
described in other documents Cenovus files from time to time with
securities regulatory authorities in Canada (available on SEDAR+ at
sedarplus.ca, on EDGAR at sec.gov and Cenovus’s website at
cenovus.com).
Cenovus Energy Inc.Cenovus Energy
Inc. is an integrated energy company with oil and natural gas
production operations in Canada and the Asia Pacific region, and
upgrading, refining and marketing operations in Canada and the
United States. Cenovus is focused on managing its assets in a safe,
innovative and cost-efficient manner, integrating environmental,
social and governance considerations into its business plans.
Cenovus common shares and warrants are listed on the Toronto and
New York stock exchanges, and the company’s preferred shares are
listed on the Toronto Stock Exchange. For more information, visit
cenovus.com.
Find Cenovus on Facebook, X, LinkedIn, YouTube and
Instagram.
Cenovus contacts
Investors |
Media |
Investor Relations general line |
Media Relations general line |
403-766-7711 |
403-766-7751 |
Cenovus Energy (TSX:CVE)
Historical Stock Chart
From Nov 2024 to Dec 2024
Cenovus Energy (TSX:CVE)
Historical Stock Chart
From Dec 2023 to Dec 2024